AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10832774 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 9381513 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide, 800 micrograms/d
Number of subjects: 16
Study 8249953 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (10 micrograms) at 0, 1, 2, and 11 months of age with hepatitis B immune globulin (0.5 mL/kg) within 2 hours of birth (group A)
Number of subjects: 80
Study 8249953 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (10 micrograms) at 3, 4, 5, and 11 months of age with hepatitis B immune globulin (0.5 mL/kg) within 2 hours of birth and a second dose at 3 months (group B)
Number of subjects: 80
Study 2876244 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based day centre (ACCEPT)
Number of subjects: 151
Study 2876244 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital inpatient and outpatient services
Number of subjects: 151
Study 30017630 — intervention group
Group type: EXPERIMENTAL
Intervention: Active working memory training (n=45)
Number of subjects: 81
Study 30017630 — intervention group
Group type: COMPARATOR
Intervention: Control working memory training (n=36)
Number of subjects: 81
Study 27362497 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-camp intervention arm (six-week day-camp focusing on increased physical activity and healthy diet followed by a one-year family-based intervention)
Number of subjects: 115
Study 27362497 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-camp intervention arm
Number of subjects: 115
Study 27362497 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention arm (one weekly exercise session for six weeks)
Number of subjects: 115
Study 24111649 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilinaster drop (5 drop/kg every eight hours) and phototherapy
Number of subjects: 90
Study 24111649 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerin suppository (half every twelve hours) and phototherapy
Number of subjects: 90
Study 24111649 — intervention group
Group type: COMPARATOR
Intervention: Control group (phototherapy only)
Number of subjects: 90
Study 22227086 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-based weaning (PBW) administered by nurses, n = 61
Number of subjects: 122
Study 22227086 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) managed by ICU physicians, n = 61
Number of subjects: 122
Study 20391208 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to boost perceived behavioural control (PBC) and create walking plans
Number of subjects: 130
Study 20391208 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting-list)
Number of subjects: 130
Study 18347602 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotyping for 492,900 single‐nucleotide polymorphisms (SNPs) using the Affymetrix 500K two‐chip genotyping platform plus a custom 164K fill‐in chip
Number of subjects: 738
Study 18347602 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analyses for SNP association with schizophrenia
Number of subjects: 738
Study 18347602 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned genomewide association study for response phenotypes
Number of subjects: 738
Study 15817848 — intervention group
Group type: COMPARATOR
Intervention: Control group (established dietary intake)
Number of subjects: 155
Study 15817848 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dairy group (calcium intake of approximately 1000-1100 mg/d)
Number of subjects: 155
Study 15817848 — intervention group
Group type: EXPERIMENTAL
Intervention: High dairy group (calcium intake of 1300-1400 mg/d)
Number of subjects: 155
Study 12512990 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest SpinBrush (experimental toothbrush)
Number of subjects: 36
Study 12512990 — intervention group
Group type: COMPARATOR
Intervention: Lion Dentor Systema (control toothbrush)
Number of subjects: 36
Study 10333815 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistive technology and environmental interventions (AT and EIs)
Number of subjects: 104
Study 10333815 — intervention group
Group type: COMPARATOR
Intervention: Usual care services (Control)
Number of subjects: 104
Study 8944191 — intervention group
Group type: COMPARATOR
Intervention: Young control group (mean age 23.3 years)
Number of subjects: 18
Study 8944191 — intervention group
Group type: COMPARATOR
Intervention: Age-matched control group (mean age 70.3 years)
Number of subjects: 18
Study 8944191 — intervention group
Group type: EXPERIMENTAL
Intervention: ARM subjects (mean age 72.3 years)
Number of subjects: 18
Study 8944191 — intervention group
Group type: COMPARATOR
Intervention: Comparison between young control group and age-matched control group
Number of subjects: 18
Study 8944191 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between ARM subjects and age-matched controls
Number of subjects: 18
Study 8944191 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between age-matched controls and ARM subjects
Number of subjects: 18
Study 1958561 — intervention group
Group type: EXPERIMENTAL
Intervention: TE-300 mg/wk
Number of subjects: 30
Study 1958561 — intervention group
Group type: EXPERIMENTAL
Intervention: ND-300 mg/wk
Number of subjects: 30
Study 1958561 — intervention group
Group type: COMPARATOR
Intervention: TE-100 mg/wk
Number of subjects: 30
Study 6765140 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid and dipyridamol (1,050 mg + 150 mg/day) - group A
Number of subjects: 66
Study 6765140 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1,200 mg/day) - group P
Number of subjects: 66
Study 6765140 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 66
Study 30704260 — intervention group
Group type: EXPERIMENTAL
Intervention: Early norepinephrine (n=155)
Number of subjects: 310
Study 30704260 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (n=155)
Number of subjects: 310
Study 27922936 — intervention group
Group type: EXPERIMENTAL
Intervention: TX‐004HR 4μg
Number of subjects: 764
Study 27922936 — intervention group
Group type: EXPERIMENTAL
Intervention: TX‐004HR 10μg
Number of subjects: 764
Study 27922936 — intervention group
Group type: EXPERIMENTAL
Intervention: TX‐004HR 25μg
Number of subjects: 764
Study 27922936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 764
Study 27922936 — intervention group
Group type: EXPERIMENTAL
Intervention: TX‐004HR (all doses)
Number of subjects: 764
Study 27922936 — intervention group
Group type: EXPERIMENTAL
Intervention: TX‐004HR
Number of subjects: 764
Study 25566954 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body positive pressure (LBPP) device at 60% body weight
Number of subjects: 11
Study 25566954 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body positive pressure (LBPP) device at 80% body weight
Number of subjects: 11
Study 25566954 — intervention group
Group type: COMPARATOR
Intervention: 100% body weight (BW)
Number of subjects: 11
Study 23444285 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release prednisone tablets (5 mg) taken at bedtime
Number of subjects: 33
Study 23444285 — intervention group
Group type: COMPARATOR
Intervention: Conventional prednisone (5 mg)
Number of subjects: 33
Study 23444285 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release prednisone tablets taken with or after an evening meal
Number of subjects: 33
Study 23444285 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release prednisone tablets taken under fasted conditions
Number of subjects: 33
Study 21833690 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive behavior therapy (CBT)
Number of subjects: 0
Study 21833690 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated behavioral and family therapy (IBFT)
Number of subjects: 0
Study 21833690 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 0
Study 21833690 — intervention group
Group type: COMPARATOR
Intervention: HIV‐specific intervention
Number of subjects: 0
Study 19217745 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 80
Study 19217745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 16930803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 16930803 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 x 5 mg cetrorelix acetate
Number of subjects: 109
Study 16930803 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 x 10 mg cetrorelix acetate
Number of subjects: 109
Study 16930803 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 10 mg cetrorelix acetate
Number of subjects: 109
Study 14985989 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibratory stimulation applied to the belly of the gastrocnemius muscles of both legs
Number of subjects: 70
Study 12063916 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiation therapy
Number of subjects: 0
Study 12063916 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study 9823484 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater interhemispheric connectivity observed in women as measured by the splenium of the corpus callosum.
Number of subjects: 114
Study 9823484 — intervention group
Group type: EXPERIMENTAL
Intervention: New image analysis technique for investigating local variability in brain morphology.
Number of subjects: 114
Study 7896672 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-session cognitive group prevention intervention
Number of subjects: 150
Study 7896672 — intervention group
Group type: COMPARATOR
Intervention: Usual care control condition
Number of subjects: 150
Study 2566287 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 7.5 mg
Number of subjects: 60
Study 2566287 — intervention group
Group type: COMPARATOR
Intervention: Temazepam 20 mg
Number of subjects: 60
Study 782969 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant WRL 105 live attenuated influenza virus vaccine
Number of subjects: 18
Study 782969 — intervention group
Group type: COMPARATOR
Intervention: Placebo nose drops
Number of subjects: 18
Study 782969 — intervention group
Group type: COMPARATOR
Intervention: Neither vaccine nor placebo
Number of subjects: 18
Study 31573247 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory error measurement for ^{43}Ca^{+} trapped-ion qubit with storage times t≲50  ms
Number of subjects: 1
Study 31573247 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized benchmarking at t=1  ms
Number of subjects: 1
Study 28816343 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivity alerts from fitness trackers (every 15 or 20 minutes of inactivity)
Number of subjects: 10
Study 28816343 — intervention group
Group type: COMPARATOR
Intervention: Reversal phase (removal of inactivity alerts)
Number of subjects: 10
Study 25417069 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic sleeve gastrectomy
Number of subjects: 409
Study 25417069 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic sleeve gastrectomy
Number of subjects: 409
Study 25417069 — intervention group
Group type: EXPERIMENTAL
Intervention: Both robotic and laparoscopic groups
Number of subjects: 409
Study 23546328 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterilized plastic fields
Number of subjects: 0
Study 23546328 — intervention group
Group type: EXPERIMENTAL
Intervention: Disinfection with 70% alcohol and 1% iodine solutions
Number of subjects: 0
Study 21473976 — intervention group
Group type: COMPARATOR
Intervention: Blacks
Number of subjects: 1331
Study 19421678 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral water soluble contrast agent (Group A)
Number of subjects: 41
Study 19421678 — intervention group
Group type: COMPARATOR
Intervention: Conventional management (Group B)
Number of subjects: 41
Study 16955991 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 138
Study 16955991 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine
Number of subjects: 138
Study 16955991 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine with lithium addition
Number of subjects: 138
Study 16955991 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine with lithium addition
Number of subjects: 138
Study 14767813 — intervention group
Group type: COMPARATOR
Intervention: Ganciclovir implant plus oral placebo
Number of subjects: 57
Study 14767813 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir implant plus oral ganciclovir
Number of subjects: 57
Study 14767813 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir
Number of subjects: 57
Study 11722963 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoovovegetarian diet
Number of subjects: 18
Study 11722963 — intervention group
Group type: COMPARATOR
Intervention: Nonvegetarian diet
Number of subjects: 18
Study 9396394 — intervention group
Group type: EXPERIMENTAL
Intervention: CADO (cyclophosphamide 300 mg/m2/d on days 1 to 5, vincristine 1.5 mg/m2/d on days 1 and 5, doxorubicin 60 mg/m2/d on day 5)
Number of subjects: 183
Study 9396394 — intervention group
Group type: EXPERIMENTAL
Intervention: CVP (cisplatin 40 mg/m2/d and etoposide 100 mg/m2/d on days 1 to 5)
Number of subjects: 183
Study 9396394 — intervention group
Group type: EXPERIMENTAL
Intervention: CADO/CVP (combined treatment)
Number of subjects: 183
Study 9396394 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion (CI) of cisplatin
Number of subjects: 183
Study 9396394 — intervention group
Group type: COMPARATOR
Intervention: Bolus (BO) of cisplatin
Number of subjects: 183
Study 9396394 — intervention group
Group type: COMPARATOR
Intervention: Both CI and BO
Number of subjects: 183
Study 8193968 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide (Buscopan)
Number of subjects: 66
Study 8193968 — intervention group
Group type: COMPARATOR
Intervention: Glucagon
Number of subjects: 66
Study 3285536 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-drug therapy (low doses of cyclosporine, azathioprine, and steroids)
Number of subjects: 100
Study 3285536 — intervention group
Group type: COMPARATOR
Intervention: Double-drug therapy (higher doses of cyclosporine plus steroids)
Number of subjects: 100
Study 30735533 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency unit utilization in 2014
Number of subjects: 619
Study 30735533 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency unit utilization in 2017
Number of subjects: 619
Study 30735533 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient care utilization in 2014
Number of subjects: 619
Study 30735533 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient care utilization in 2017
Number of subjects: 619
Study 30735533 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization rates in 2014
Number of subjects: 619
Study 30735533 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization rates in 2017
Number of subjects: 619
Study 30735533 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in emergency unit utilization
Number of subjects: 619
Study 28110270 — intervention group
Group type: EXPERIMENTAL
Intervention: Lancet
Number of subjects: 40
Study 28110270 — intervention group
Group type: COMPARATOR
Intervention: 26-gauge needle
Number of subjects: 40
Study 25456290 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld electrocautery device on 'coagulation setting'
Number of subjects: 102
Study 25456290 — intervention group
Group type: COMPARATOR
Intervention: Sharp dissection with scalpel and monopolar electrocautery forceps
Number of subjects: 102
Study 25456290 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposuction at the time of abdominoplasty
Number of subjects: 102
Study 23451237 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=277)
Number of subjects: 559
Study 23451237 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=282)
Number of subjects: 559
Study 21877762 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg (DEX group, n=21)
Number of subjects: 42
Study 21877762 — intervention group
Group type: COMPARATOR
Intervention: Control group (C group, n=21)
Number of subjects: 42
Study 19176296 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniaturized extracorporeal circuits (MEC)
Number of subjects: 450
Study 19176296 — intervention group
Group type: COMPARATOR
Intervention: Conventional bypass
Number of subjects: 450
Study 16501636 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg/kg G-CSF for 6 days after percutaneous coronary intervention
Number of subjects: 50
Study 16501636 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 50
Study 12802879 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg cortisol
Number of subjects: 90
Study 12802879 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg cortisol
Number of subjects: 90
Study 12802879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 10992963 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivazerol
Number of subjects: 36
Study 10992963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 8797976 — intervention group
Group type: EXPERIMENTAL
Intervention: Whitacre spinal needle
Number of subjects: 100
Study 8797976 — intervention group
Group type: COMPARATOR
Intervention: Quincke spinal needle
Number of subjects: 100
Study 1510446 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin 5 mg/kg once daily
Number of subjects: 144
Study 1510446 — intervention group
Group type: COMPARATOR
Intervention: Netilmicin 2 mg/kg thrice daily
Number of subjects: 144
Study 6649721 — intervention group
Group type: EXPERIMENTAL
Intervention: Sauna bath
Number of subjects: 0
Study 6649721 — intervention group
Group type: EXPERIMENTAL
Intervention: Running treatment
Number of subjects: 0
Study 6649721 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30816124 — intervention group
Group type: EXPERIMENTAL
Intervention: Ologen (placed over the valve's plate)
Number of subjects: 58
Study 30816124 — intervention group
Group type: COMPARATOR
Intervention: Control group (Conventional surgery with Ahmed valve)
Number of subjects: 58
Study 29504578 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 97
Study 29504578 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection (CSI)
Number of subjects: 97
Study 26385599 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate Day Fasting (ADF)
Number of subjects: 121
Study 24947080 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical limb ischemia (CLI) patients
Number of subjects: 37
Study 24947080 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 37
Study 22958958 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI with renal artery denervation
Number of subjects: 27
Study 22958958 — intervention group
Group type: COMPARATOR
Intervention: PVI only
Number of subjects: 27
Study 20580483 — intervention group
Group type: EXPERIMENTAL
Intervention: ERSPC risk calculator
Number of subjects: 525
Study 20580483 — intervention group
Group type: COMPARATOR
Intervention: PCPT risk calculator
Number of subjects: 525
Study 20580483 — intervention group
Group type: COMPARATOR
Intervention: PSA alone
Number of subjects: 525
Study 20580483 — intervention group
Group type: COMPARATOR
Intervention: PCPT model
Number of subjects: 525
Study 18076236 — intervention group
Group type: EXPERIMENTAL
Intervention: Kayak ergometer protocol
Number of subjects: 15
Study 18076236 — intervention group
Group type: COMPARATOR
Intervention: Arm crank protocol
Number of subjects: 15
Study 11730588 — intervention group
Group type: EXPERIMENTAL
Intervention: Neodosis software package
Number of subjects: 54
Study 11730588 — intervention group
Group type: COMPARATOR
Intervention: No computer support (control)
Number of subjects: 54
Study 9454384 — intervention group
Group type: EXPERIMENTAL
Intervention: Various hemostasis indexes
Number of subjects: 30
Study 9454384 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin index, activated partial thromboplastin index
Number of subjects: 30
Study 9454384 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin's inactive forms (prethrombin‐1, decarboxylated prethrombin etc.), ecamulin index
Number of subjects: 30
Study 9454384 — intervention group
Group type: EXPERIMENTAL
Intervention: Velocity bend of distraction of fibrin clot, velocity bend of forming of fibrin clot, height of clot using turbidimetric method
Number of subjects: 30
Study 9454384 — intervention group
Group type: EXPERIMENTAL
Intervention: Half‐lysis time, lysis time, time of fibrin clot using turbidimetric method
Number of subjects: 30
Study 9454384 — intervention group
Group type: EXPERIMENTAL
Intervention: Velocity, Intensity, remainder of platelet aggregation induced by ADP 10 mcg/ml, 2.5 mcg/ml, 1.9 mcg/ml
Number of subjects: 30
Study 9454384 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombin time
Number of subjects: 30
Study 9454384 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein C
Number of subjects: 30
Study 9454384 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen
Number of subjects: 30
Study 9454384 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet count
Number of subjects: 30
Study 9454384 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble fibrin
Number of subjects: 30
Study 9454384 — intervention group
Group type: EXPERIMENTAL
Intervention: Ancystron time
Number of subjects: 30
Study 9454384 — intervention group
Group type: EXPERIMENTAL
Intervention: X factor
Number of subjects: 30
Study 9454384 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin‐III
Number of subjects: 30
Study 9454384 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin(ogen) degradation products
Number of subjects: 30
Study 8216397 — intervention group
Group type: EXPERIMENTAL
Intervention: cM‐T412 50 mg
Number of subjects: 32
Study 8216397 — intervention group
Group type: EXPERIMENTAL
Intervention: cM‐T412 100 mg
Number of subjects: 32
Study 8216397 — intervention group
Group type: EXPERIMENTAL
Intervention: cM‐T412 10 mg
Number of subjects: 32
Study 3688417 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine anesthesia
Number of subjects: 240
Study 3688417 — intervention group
Group type: COMPARATOR
Intervention: No topical lidocaine anesthesia (Control)
Number of subjects: 240
Study 29757876 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended carboplatin infusion (3-hour infusion)
Number of subjects: 146
Study 29757876 — intervention group
Group type: COMPARATOR
Intervention: Standard carboplatin infusion (30-minute infusion)
Number of subjects: 146